Stock SEZI SENZIME AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Senzime AB

Equities

SEZI

SE0002478776

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:31 2024-06-07 am EDT 		5-day change 1st Jan Change
6.96 SEK +0.14% Intraday chart for Senzime AB +3.88% -6.33%
Jun. 07 Senzime Wins Contract with the Most Prestigious and Highest Ranked Children's Hospital in the US CI
May. 21 New Clinical Study Published in Anesthesiology Confirms the Leading Accuracy and Precision of Senzime's TetraGraph System CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SENZIME AB Stock Senzime AB
-6.33% 79.05M
C
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.26% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
+2.05% 110B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-1.31% 69.54B
A
CENCORA, INC. Stock Cencora, Inc.
+14.65% 46.37B
B-
DEXCOM, INC. Stock DexCom, Inc.
-6.69% 46.05B
B-
HOYA CORPORATION Stock Hoya Corporation
+7.97% 42.54B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+18.60% 30.72B
B
TERUMO CORPORATION Stock Terumo Corporation
+16.92% 25.62B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-6.87% 23.32B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. SEZI Stock
  4. Ratings Senzime AB